Belgium’s Hyloris Pharmaceuticals has so far enjoyed a fruitful 2020. Having kicked off the year with a funding round that raised €15m ($17.6m) for the value-added medicines developer (Also see "Hyloris Funding Round Raises €15m" - Generics Bulletin, 4 May, 2020.), the firm more recently announced an initial public offering to give it the funding it needs to pursue opportunities through the US hybrid 505(b)(2) regulatory pathway. (Also see "Value-Added Specialist Hyloris Launches IPO" - Generics Bulletin, 3 June, 2020.) This ultimately resulted in proceeds of €61.81m, or approximately €71.08m assuming the exercise in full of the IPO’s over-allotment option.
Hyloris Lays Out Ambitious Plans For US
Value Added Medicines Specialist Reveals How It Will Use IPO Proceeds
Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.
